The guideline creation committee made every effort to avoid actual or potential conflicts of interest to enable its members to perform their duties in a neutral and fair manner. All members and academic societies involved in guideline creation disclosed potential or actual conflicts of interest. The disclosure criteria were set according to the “Guidance on eligibility criteria for participation in the development of clinical practice guidelines” by the Japanese Association of Medical Sciences, with the target period from January 1, 2019, to December 31, 2021.

Information on the conflicts of interest of the members and organizations of the Japanese Society of Neuropsychopharmacology and Japanese Society of Clinical Neuropsychopharmacology, which created the guideline, is provided at the end of this document.

None.